Omeros (OMER) Competitors

Omeros logo
$16.68 -0.81 (-4.63%)
Closing price 04:00 PM Eastern
Extended Trading
$15.61 -1.07 (-6.41%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OMER vs. ERAS, TVTX, CRSP, DNTH, and CDNA

Should you buy Omeros stock or one of its competitors? Omeros's main competitors and comparable companies include Erasca (ERAS), Travere Therapeutics (TVTX), CRISPR Therapeutics (CRSP), Dianthus Therapeutics (DNTH), and CareDx (CDNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Omeros compare to Erasca?

Erasca (NASDAQ:ERAS) and Omeros (NASDAQ:OMER) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Erasca's return on equity of -31.63% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
ErascaN/A -31.63% -27.57%
Omeros N/A -164.92%69.41%

Erasca presently has a consensus price target of $22.09, suggesting a potential upside of 41.07%. Omeros has a consensus price target of $30.33, suggesting a potential upside of 73.43%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than Erasca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Erasca
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

Erasca has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Omeros has a beta of 2.96, meaning that its stock price is 196% more volatile than the broader market.

In the previous week, Erasca had 9 more articles in the media than Omeros. MarketBeat recorded 14 mentions for Erasca and 5 mentions for Omeros. Omeros' average media sentiment score of 0.13 beat Erasca's score of 0.08 indicating that Omeros is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Erasca
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omeros
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

67.8% of Erasca shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 10.5% of Omeros shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Omeros has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ErascaN/AN/A-$124.55M-$0.95N/A
Omeros$38.42M32.95-$3.35M$1.2813.66

Summary

Omeros beats Erasca on 8 of the 14 factors compared between the two stocks.

How does Omeros compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Omeros (NASDAQ:OMER) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Travere Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Omeros has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to Travere Therapeutics' net margin of -18.66%. Omeros' return on equity of -164.92% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Travere Therapeutics-18.66% -185.69% -17.24%
Omeros N/A -164.92%69.41%

In the previous week, Travere Therapeutics and Travere Therapeutics both had 5 articles in the media. Travere Therapeutics' average media sentiment score of 0.57 beat Omeros' score of 0.13 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Omeros
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Omeros has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$651.03M7.47-$25.55M-$1.29N/A
Omeros$38.42M32.95-$3.35M$1.2813.66

Travere Therapeutics presently has a consensus price target of $72.55, indicating a potential upside of 43.23%. Omeros has a consensus price target of $30.33, indicating a potential upside of 73.43%. Given Omeros' higher possible upside, analysts plainly believe Omeros is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.69
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

48.8% of Omeros shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Omeros beats Travere Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Omeros compare to CRISPR Therapeutics?

Omeros (NASDAQ:OMER) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Omeros has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
OmerosN/A -164.92% 69.41%
CRISPR Therapeutics -1,812.07%-25.59%-17.89%

Omeros currently has a consensus price target of $30.33, suggesting a potential upside of 73.43%. CRISPR Therapeutics has a consensus price target of $72.93, suggesting a potential upside of 72.65%. Given Omeros' higher possible upside, equities research analysts clearly believe Omeros is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.65

48.8% of Omeros shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Omeros has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omeros$38.42M32.95-$3.35M$1.2813.66
CRISPR Therapeutics$3.51M1,167.32-$581.60M-$4.74N/A

Omeros has a beta of 2.96, suggesting that its share price is 196% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 12 more articles in the media than Omeros. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 5 mentions for Omeros. CRISPR Therapeutics' average media sentiment score of 0.15 beat Omeros' score of 0.13 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omeros
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
CRISPR Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summary

Omeros beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Omeros compare to Dianthus Therapeutics?

Omeros (NASDAQ:OMER) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Omeros has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

Omeros presently has a consensus price target of $30.33, suggesting a potential upside of 73.43%. Dianthus Therapeutics has a consensus price target of $128.77, suggesting a potential upside of 40.26%. Given Omeros' higher possible upside, research analysts plainly believe Omeros is more favorable than Dianthus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00

48.8% of Omeros shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Dianthus Therapeutics had 23 more articles in the media than Omeros. MarketBeat recorded 28 mentions for Dianthus Therapeutics and 5 mentions for Omeros. Dianthus Therapeutics' average media sentiment score of 0.61 beat Omeros' score of 0.13 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omeros
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Dianthus Therapeutics
9 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Omeros has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omeros$38.42M32.95-$3.35M$1.2813.66
Dianthus Therapeutics$2.04M2,534.23-$162.34M-$3.99N/A

Omeros has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -7,436.50%. Dianthus Therapeutics' return on equity of -19.68% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
OmerosN/A -164.92% 69.41%
Dianthus Therapeutics -7,436.50%-19.68%-18.95%

Summary

Omeros beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Omeros compare to CareDx?

Omeros (NASDAQ:OMER) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, CareDx had 9 more articles in the media than Omeros. MarketBeat recorded 14 mentions for CareDx and 5 mentions for Omeros. CareDx's average media sentiment score of 0.59 beat Omeros' score of 0.13 indicating that CareDx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omeros
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
CareDx
4 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

48.8% of Omeros shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 2.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Omeros has a beta of 2.96, indicating that its stock price is 196% more volatile than the broader market. Comparatively, CareDx has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

Omeros presently has a consensus price target of $30.33, indicating a potential upside of 73.43%. CareDx has a consensus price target of $70.33, indicating a potential downside of 9.69%. Given Omeros' higher possible upside, equities research analysts clearly believe Omeros is more favorable than CareDx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
CareDx
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.67

CareDx has a net margin of 25.86% compared to Omeros' net margin of 0.00%. CareDx's return on equity of 9.74% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
OmerosN/A -164.92% 69.41%
CareDx 25.86%9.74%7.35%

Omeros has higher earnings, but lower revenue than CareDx. Omeros is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omeros$38.42M32.95-$3.35M$1.2813.66
CareDx$379.80M10.77-$21.35M$2.3932.59

Summary

CareDx beats Omeros on 10 of the 17 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OMER vs. The Competition

MetricOmerosBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.30B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio6.5926.5532.9127.39
Price / SalesN/A16.028.595.74
Price / Cash9.6126.3721.9322.50
Price / Book-9.754.074.403.70
Net Income-$3.35M-$22.86M$3.52B$392.17M
7 Day Performance-4.96%-7.26%-5.34%-4.53%
1 Month Performance2.96%-4.96%-3.61%-5.86%
1 Year Performance111.94%-2.87%0.01%-7.78%

Omeros Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OMER
Omeros
2.9641 of 5 stars
$16.68
-4.6%
$30.33
+81.9%
+122.2%$1.30BN/A6.59175
ERAS
Erasca
1.6802 of 5 stars
$15.61
+8.3%
$22.09
+41.5%
+507.0%$5.21BN/AN/A103
TVTX
Travere Therapeutics
3.6474 of 5 stars
$51.63
+4.1%
$72.55
+40.5%
+46.8%$5.03B$490.73MN/A497
CRSP
CRISPR Therapeutics
2.8414 of 5 stars
$50.04
-0.1%
$69.69
+39.3%
-19.6%$5.02B$3.51MN/A393
DNTH
Dianthus Therapeutics
2.2704 of 5 stars
$90.00
+4.6%
$128.77
+43.1%
+124.7%$4.70B$2.04MN/A92

Related Companies and Tools


This page (NASDAQ:OMER) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners